Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Public ClinicalTrials.gov record NCT06510504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder
Study identification
- NCT ID
- NCT06510504
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bionomics Limited
- Industry
- Enrollment
- 370 participants
Conditions and interventions
Conditions
Interventions
- 225 mg BNC210 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2024
- Primary completion
- Sep 10, 2025
- Completion
- Sep 18, 2025
- Last update posted
- May 18, 2026
2024 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AFFIRM-1 Study Site | Encino | California | 91316 | — |
| AFFIRM-1 Study Site | La Jolla | California | 92037 | — |
| AFFIRM-1 Study Site | Los Angeles | California | 90025 | — |
| AFFIRM-1 Study Site | Oceanside | California | 92056 | — |
| AFFIRM-1 Study Site | San Diego | California | 92103 | — |
| AFFIRM-1 Study Site | San Jose | California | 95124 | — |
| AFFIRM-1 Study Site | Sherman Oaks | California | 91403 | — |
| AFFIRM-1 Study Site | Temecula | California | 92591 | — |
| AFFIRM-1 Study Site | Jacksonville | Florida | 32256 | — |
| AFFIRM-1 Study Site | Lauderhill | Florida | 33319 | — |
| AFFIRM-1 Study Site | Miami Lakes | Florida | 33016 | — |
| AFFIRM-1 Study Site | Orlando | Florida | 32801 | — |
| AFFIRM-1 Study Site | Tampa | Florida | 33607 | — |
| AFFIRM-1 Study Site | Decatur | Georgia | 30030 | — |
| AFFIRM-1 Study Site | Boston | Massachusetts | 02114 | — |
| AFFIRM-1 Study Site | Boston | Massachusetts | 02131 | — |
| AFFIRM-1 Study Site | Princeton | New Jersey | 08540 | — |
| AFFIRM-1 Study Site | Brooklyn | New York | 11229 | — |
| AFFIRM-1 Study Site | Charlotte | North Carolina | 28211 | — |
| AFFIRM-1 Study Site | Media | Pennsylvania | 19063 | — |
| AFFIRM-1 Study Site | Austin | Texas | 78737 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06510504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06510504 live on ClinicalTrials.gov.